Trop2: A possible therapeutic target for late stage epithelial carcinomas

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1796, Issue 2, 2009, Pages 309-314

  Cubas, Rafael ^a   Li, Min ^a   Chen, Changyi ^a   Yao, Qizhi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Epithelial carcinomas; Oncogene; Trop2; Tumor metastasis

Indexed keywords

CELL SURFACE PROTEIN; CYCLIN D1; EDRECOLOMAB; EPITHELIAL CELL ADHESION MOLECULE; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RS7-3G11; PROTEIN TROP2; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CANCER STAGING; COLON CANCER; COLORECTAL CANCER; CORNEA DYSTROPHY; DRUG TARGETING; HUMAN; LIVER CELL; MALIGNANT NEOPLASTIC DISEASE; MOUTH CARCINOMA; MULTIGENE FAMILY; NONHUMAN; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STEM CELL; STOMACH CANCER;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; GENES, BCL-1; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; ONCOGENES;

EID: 70349175559     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2009.08.001     Document Type: Review

References (53)

1. Fong D., Moser P., Krammel C., Gostner J.M., Margreiter R., Mitterer M., Gastl G., and Spizzo G. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br. J. Cancer 99 (2008) 1290-1295
2. Fong D., Spizzo G., Gostner J.M., Gastl G., Moser P., Krammel C., Gerhard S., Rasse M., and Laimer K. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod. Pathol. 21 (2008) 186-191
3. Muhlmann G., Spizzo G., Gostner J., Zitt M., Mair H., Moser P., Gastl G., Muller H.M., Margreiter R., Ofner D., and Fong D. TROP2 expression as prognostic marker for gastric carcinoma. J. Clin. Pathol. 62 (2009) 152-158
4. Nakashima K., Shimada H., Ochiai T., Kuboshima M., Kuroiwa N., Okazumi S., Matsubara H., Nomura F., Takiguchi M., and Hiwasa T. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int. J. Cancer 112 (2004) 1029-1035
5. Ohmachi T., Tanaka F., Mimori K., Inoue H., Yanaga K., and Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin. Cancer Res. 12 (2006) 3057-3063
6. Lipinski M., Parks D.R., Rouse R.V., and Herzenberg L.A. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 5147-5150
7. Bischof P., Meisser A., and Campana A. Biochemistry and molecular biology of trophoblast invasion. Ann. N. Y. Acad. Sci. 943 (2001) 157-162
8. Knofler M., Simmons D.G., Lash G.E., Harris L.K., and Armant D.R. Regulation of trophoblast invasion - a workshop report. Placenta 29 Suppl A (2008) S26-S28
9. Wang J., Day R., Dong Y., Weintraub S.J., and Michel L. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol. Cancer Ther. 7 (2008) 280-285
10. Zhang L., Zhou W., Velculescu V.E., Kern S.E., Hruban R.H., Hamilton S.R., Vogelstein B., and Kinzler K.W. Gene expression profiles in normal and cancer cells. Science 276 (1997) 1268-1272
11. Linnenbach A.J., Wojcierowski J., Wu S.A., Pyrc J.J., Ross A.H., Dietzschold B., Speicher D., and Koprowski H. Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 27-31
12. 2-binding sequence in the cytoplasmic domain of TROP-2. Int. J. Cancer 75 (1998) 324-330
13. Linnenbach A.J., Seng B.A., Wu S., Robbins S., Scollon M., Pyrc J.J., Druck T., and Huebner K. Retroposition in a family of carcinoma-associated antigen genes. Mol. Cell. Biol. 13 (1993) 1507-1515
14. Yu F.X., Sun H.Q., Janmey P.A., and Yin H.L. Identification of a polyphosphoinositide-binding sequence in an actin monomer-binding domain of gelsolin. J. Biol. Chem. 267 (1992) 14616-14621
15. Nomura T., and Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J. Med. Invest. 52 (2005) 1-9
16. Baeuerle P.A., and Gires O. EpCAM (CD326) finding its role in cancer. Br. J. Cancer 96 (2007) 417-423
17. Trzpis M., McLaughlin P.M., de Leij L.M., and Harmsen M.C. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am. J. Pathol. 171 (2007) 386-395
18. Litvinov S.V., Balzar M., Winter M.J., Bakker H.A., Briaire-de Bruijn I.H., Prins F., Fleuren G.J., and Warnaar S.O. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J. Cell Biol. 139 (1997) 1337-1348
19. Osta W.A., Chen Y., Mikhitarian K., Mitas M., Salem M., Hannun Y.A., Cole D.J., and Gillanders W.E. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 64 (2004) 5818-5824
20. Schmidt D.S., Klingbeil P., Schnolzer M., and Zoller M. CD44 variant isoforms associate with tetraspanins and EpCAM. Exp. Cell Res. 297 (2004) 329-347
21. Munz M., Kieu C., Mack B., Schmitt B., Zeidler R., and Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23 (2004) 5748-5758
22. Munz M., Baeuerle P.A., and Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 69 (2009) 5627-5629
23. Spizzo G., Went P., Dirnhofer S., Obrist P., Simon R., Spichtin H., Maurer R., Metzger U., von Castelberg B., Bart R., Stopatschinskaya S., Kochli O.R., Haas P., Mross F., Zuber M., Dietrich H., Bischoff S., Mirlacher M., Sauter G., and Gastl G. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res. Treat. 86 (2004) 207-213
24. Spizzo G., Went P., Dirnhofer S., Obrist P., Moch H., Baeuerle P.A., Mueller-Holzner E., Marth C., Gastl G., and Zeimet A.G. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol. Oncol. 103 (2006) 483-488
25. Seligson D.B., Pantuck A.J., Liu X., Huang Y., Horvath S., Bui M.H., Han K.R., Correa A.J., Eeva M., Tze S., Belldegrun A.S., and Figlin R.A. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin. Cancer Res. 10 (2004) 2659-2669
26. Pauli C., Munz M., Kieu C., Mack B., Breinl P., Wollenberg B., Lang S., Zeidler R., and Gires O. Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas. Cancer Lett. 193 (2003) 25-32
27. Punt C.J., Nagy A., Douillard J.Y., Figer A., Skovsgaard T., Monson J., Barone C., Fountzilas G., Riess H., Moylan E., Jones D., Dethling J., Colman J., Coward L., and MacGregor S. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 360 (2002) 671-677
28. Hartung G., Hofheinz R.D., Dencausse Y., Sturm J., Kopp-Schneider A., Dietrich G., Fackler-Schwalbe I., Bornbusch D., Gonnermann M., Wojatschek C., Lindemann W., Eschenburg H., Jost K., Edler L., Hochhaus A., and Queisser W. Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie 28 (2005) 347-350
29. Sankpal N.V., Willman M.W., Fleming T.P., Mayfield J.D., and Gillanders W.E. Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. Cancer Res. 69 (2009) 753-757
30. Basu A., Goldenberg D.M., and Stein R. The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. Int. J. Cancer 62 (1995) 472-479
31. Linder S., and Aepfelbacher M. Podosomes: adhesion hot-spots of invasive cells. Trends Cell Biol. 13 (2003) 376-385
32. Linder S., Nelson D., Weiss M., and Aepfelbacher M. Wiskott-Aldrich syndrome protein regulates podosomes in primary human macrophages. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 9648-9653
33. Burns S., Thrasher A.J., Blundell M.P., Machesky L., and Jones G.E. Configuration of human dendritic cell cytoskeleton by Rho GTPases, the WAS protein, and differentiation. Blood 98 (2001) 1142-1149
34. Mizutani K., Miki H., He H., Maruta H., and Takenawa T. Essential role of neural Wiskott-Aldrich syndrome protein in podosome formation and degradation of extracellular matrix in src-transformed fibroblasts. Cancer Res. 62 (2002) 669-674
35. Gimona M., Kaverina I., Resch G.P., Vignal E., and Burgstaller G. Calponin repeats regulate actin filament stability and formation of podosomes in smooth muscle cells. Mol. Biol. Cell 14 (2003) 2482-2491
36. Sechi A.S., and Wehland J. The actin cytoskeleton and plasma membrane connection: PtdIns(4, 5)P(2) influences cytoskeletal protein activity at the plasma membrane. J. Cell Sci. 113 Pt 21 (2000) 3685-3695
37. Sun H.Q., Yamamoto M., Mejillano M., and Yin H.L. Gelsolin, a multifunctional actin regulatory protein. J. Biol. Chem. 274 (1999) 33179-33182
38. Ripani E., Sacchetti A., Corda D., and Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int. J. Cancer 76 (1998) 671-676
39. Tatin F., Varon C., Genot E., and Moreau V. A signalling cascade involving PKC, Src and Cdc42 regulates podosome assembly in cultured endothelial cells in response to phorbol ester. J. Cell Sci. 119 (2006) 769-781
40. Taylor J.T., Zeng X.B., Pottle J.E., Lee K., Wang A.R., Yi S.G., Scruggs J.A., Sikka S.S., and Li M. Calcium signaling and T-type calcium channels in cancer cell cycling. World J. Gastroenterol. 14 (2008) 4984-4991
41. Guerra E., Trerotola M., Dell' Arciprete R., Bonasera V., Palombo B., El-Sewedy T., Ciccimarra T., Crescenzi C., Lorenzini F., Rossi C., Vacca G., Lattanzio R., Piantelli M., and Alberti S. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res. 68 (2008) 8113-8121
42. Biliran Jr. H., Wang Y., Banerjee S., Xu H., Heng H., Thakur A., Bollig A., Sarkar F.H., and Liao J.D. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin. Cancer Res. 11 (2005) 6075-6086
43. Nelsen C.J., Kuriyama R., Hirsch B., Negron V.C., Lingle W.L., Goggin M.M., Stanley M.W., and Albrecht J.H. Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J. Biol. Chem. 280 (2005) 768-776
44. Goldstein A.S., Lawson D.A., Cheng D., Sun W., Garraway I.P., and Witte O.N. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 20882-20887
45. Okabe M., Tsukahara Y., Tanaka M., Suzuki K., Saito S., Kamiya Y., Tsujimura T., Nakamura K., and Miyajima A. Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver. Development 136 (2009) 1951-1960
46. Tsujikawa M., Kurahashi H., Tanaka T., Nishida K., Shimomura Y., Tano Y., and Nakamura Y. Identification of the gene responsible for gelatinous drop-like corneal dystrophy. Nat. Genet. 21 (1999) 420-423
47. Markoff A., Bogdanova N., Uhlig C.E., Groppe M., Horst J., and Kennerknecht I. A novel TACSTD2 gene mutation in a Turkish family with a gelatinous drop-like corneal dystrophy. Mol. Vis. 12 (2006) 1473-1476
48. Mosolits S., Markovic K., Frodin J.E., Virving L., Magnusson C.G., Steinitz M., Fagerberg J., and Mellstedt H. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin. Cancer Res. 10 (2004) 5391-5402
49. Filipits M., Pohl G., Rudas M., Dietze O., Lax S., Grill R., Pirker R., Zielinski C.C., Hausmaninger H., Kubista E., Samonigg H., and Jakesz R. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol. 23 (2005) 1161-1168
50. de Bono J.S., Tolcher A.W., Forero A., Vanhove G.F., Takimoto C., Bauer R.J., Hammond L.A., Patnaik A., White M.L., Shen S., Khazaeli M.B., Rowinsky E.K., and LoBuglio A.F. ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin. Cancer Res. 10 (2004) 7555-7565
51. Mangino G., Grazia Capri M., Barnaba V., and Alberti S. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells. Int. J. Cancer 101 (2002) 353-359
52. Stein R., Basu A., Chen S., Shih L.B., and Goldenberg D.M. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int. J. Cancer 55 (1993) 938-946
53. Govindan S.V., Stein R., Qu Z., Chen S., Andrews P., Ma H., Hansen H.J., Griffiths G.L., Horak I.D., and Goldenberg D.M. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res. Treat. 84 (2004) 173-182